Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Matthew Keller reiterates FibroGen (NASDAQ:FGEN) with a Buy and maintains $43 price target.
FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a p...
Sale of FibroGen China remains on track to close in 3Q 2025
Recent Developments and Key Highlights of Second Quarter 2025: Sale of FibroGen China to AstraZeneca now expected to be for a t...
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(2.25) by 1...
